

Jahangir Abdi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10665096/publications.pdf>

Version: 2024-02-01

12
papers

592
citations

759055

12
h-index

1199470

12
g-index

12
all docs

12
docs citations

12
times ranked

1189
citing authors

#	ARTICLE	IF	CITATIONS
1	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. <i>Oncotarget</i> , 2013, 4, 2186-2207.	0.8	145
2	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 2399-2411.	3.2	106
3	Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. <i>Leukemia</i> , 2018, 32, 2471-2482.	3.3	63
4	Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. <i>Journal of Hematology and Oncology</i> , 2017, 10, 169.	6.9	55
5	Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 121.	6.9	50
6	Role of micro-RNAs in drug resistance of multiple myeloma. <i>Oncotarget</i> , 2016, 7, 60723-60735.	0.8	37
7	Characterization of the Toll-like Receptor Expression Profile in Human Multiple Myeloma Cells. <i>PLoS ONE</i> , 2013, 8, e60671.	1.1	30
8	Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment. <i>Biomarker Research</i> , 2014, 2, 10.	2.8	29
9	miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. <i>Oncotarget</i> , 2016, 7, 7149-7160.	0.8	29
10	Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. <i>BMC Cancer</i> , 2019, 19, 975.	1.1	19
11	Toll-Like Receptor (TLR)-1/2 Triggering of Multiple Myeloma Cells Modulates Their Adhesion to Bone Marrow Stromal Cells and Enhances Bortezomib-Induced Apoptosis. <i>PLoS ONE</i> , 2014, 9, e96608.	1.1	15
12	The role of Toll-like receptor mediated signalling in the pathogenesis of multiple myeloma. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 225-240.	2.0	14